Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Clinical Diagnostics Insider
(formerly Diagnostic Testing and Emerging Technologies)
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
A Closer Lab-Patient Connection
Patient access to data from the clinical lab is increasing. What does this mean for those generating it?
New and Improved: The Latest Research in Disease Screening
New ideas and innovations look beyond conventional screening options to facilitate improved disease diagnosis and patient outcomes
Decoding Quality Terminology
There is a lot of talk about quality these days, but there is often confusion around quality terminology
Lean Six Sigma is Not Quality
By Jennifer Dawson, MHA, LSSBB, DLM(ASCP) bio
Now before the entire industry lynches me for the sacrilege of the title of this article, let me explain what I mean. I have known Lean Six Sigma skeptics and outright haters and trust me…
Protein Patterns Investigated for Markers of Early Ovarian Cancer
From - Diagnostic Testing & Emerging Technologies
The combination of liquid chromatography and tandem mass spectrometry enabled the discovery of four biomarkers holding promise to become…
By the Numbers: Lab Injury and Exposure Data
By Dan Scungio, MT (ASCP), SLS, CQA (ASQ) bio
Finding information about the number of Laboratory Acquired Infections (LAIs) and other laboratory injuries in the United States is difficult…
Lessons from Ebola Can Enhance Future Diagnostic Preparedness
...
Already a member? Log in here
Inside the Diagnostics Industry: At-Home Testing Options Expanding
...
Already a member? Log in here
IgE Testing May Be Underused in Dermatology
...
Already a member? Log in here
Utility of Whole-Genome Sequencing in Primary Care Uncertain
...
Already a member? Log in here
Companion Diagnostics Driving New Model for Pharma-Dx Partnerships
US oncology patients are missing out on targeted therapies due to a combination of testing "quality gaps" and slow test diffusion
FDA Approves First Companion Diagnostic Panel
...
Already a member? Log in here